← Back to Analyst Consensus 
PLRX Hold
PLIANT THERAPEUTICS, INC.
Current Price —
Implied Upside —
Analysts 9
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Mar 13, 2026 | Canaccord Genuity | maintain | Hold → Hold | — | 48% |
| Mar 12, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| Nov 7, 2025 | RBC Capital | maintain | Sector Perform → Sector Perform | $2 | 55% |
| Oct 10, 2025 | JP Morgan | downgrade | Neutral → Underweight | $0 | 55% |
| Aug 8, 2025 | Piper Sandler | maintain | Overweight → Overweight | $4 | 54% |
| Mar 18, 2025 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $0 | 44% |
| Mar 4, 2025 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $0 | 44% |
| Mar 4, 2025 | Citigroup | maintain | Neutral → Neutral | $1.5 | 54% |
| Mar 4, 2025 | RBC Capital | maintain | Sector Perform → Sector Perform | $3 | 55% |
| Mar 4, 2025 | Wells Fargo | maintain | Equal-Weight → Equal-Weight | $3 | 54% |
| Mar 4, 2025 | Needham | downgrade | Buy → Hold | $10 | 50% |
| Mar 3, 2025 | Leerink Partners | downgrade | Outperform → Market Perform | $2 | 51% |
| Feb 14, 2025 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $0 | 44% |
| Feb 14, 2025 | Needham | reiterate | Buy → Buy | $10 | 50% |
| Feb 10, 2025 | JP Morgan | downgrade | Overweight → Neutral | $0 | 55% |
| Feb 10, 2025 | RBC Capital | downgrade | Outperform → Sector Perform | $4 | 55% |
| Feb 10, 2025 | Canaccord Genuity | downgrade | Buy → Hold | $4 | 48% |
| Feb 10, 2025 | Wells Fargo | downgrade | Overweight → Equal-Weight | $4 | 54% |
| Feb 10, 2025 | Citigroup | downgrade | Buy → Neutral | $4 | 54% |
| Feb 10, 2025 | Needham | maintain | Buy → Buy | $10 | 50% |
| Feb 10, 2025 | HC Wainwright & Co. | downgrade | Buy → Neutral | $0 | 44% |
| Nov 8, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $38 | 44% |
| Sep 13, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $38 | 44% |
| Aug 12, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $38 | 44% |
| Aug 8, 2024 | Cantor Fitzgerald | reiterate | — → Overweight | $0 | 50% |
| Aug 8, 2024 | Oppenheimer | maintain | Outperform → Outperform | $45 | 52% |
| Aug 8, 2024 | Needham | reiterate | Buy → Buy | $38 | 50% |
| Jul 16, 2024 | Needham | reiterate | Buy → Buy | $38 | 50% |
| Jul 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $36 | 44% |
| Jun 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $36 | 44% |
| May 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $36 | 44% |
| May 7, 2024 | Citigroup | maintain | Buy → Buy | $44 | 54% |
| May 7, 2024 | RBC Capital | maintain | Outperform → Outperform | $45 | 55% |
| May 7, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $48 | 52% |
| May 7, 2024 | Needham | reiterate | Buy → Buy | $38 | 50% |
| May 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $36 | 44% |
| Apr 10, 2024 | Needham | reiterate | Buy → Buy | $38 | 50% |
| Mar 12, 2024 | Needham | reiterate | Buy → Buy | $38 | 50% |
| Mar 5, 2024 | RBC Capital | maintain | Outperform → Outperform | $54 | 55% |
| Feb 28, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $48 | 44% |
| Feb 28, 2024 | RBC Capital | maintain | Outperform → Outperform | $50 | 55% |
| Feb 28, 2024 | Needham | reiterate | Buy → Buy | $38 | 50% |
| Feb 5, 2024 | Needham | maintain | Buy → Buy | $38 | 50% |
| Feb 5, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $48 | 44% |
| Nov 10, 2023 | RBC Capital | maintain | Outperform → Outperform | $53 | 55% |
| Oct 4, 2023 | Needham | reiterate | Buy → Buy | $45 | 50% |
| Sep 27, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $52 | 44% |
| Sep 27, 2023 | Needham | reiterate | Buy → Buy | $45 | 50% |
| Sep 15, 2023 | Needham | reiterate | Buy → Buy | $45 | 50% |
| Aug 29, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $50 | 44% |
Price Target Trend
Apr 7, 2026 Oct 26, 2026
EPS Estimates
0y —
+1y —
+1q —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days